UNC Lineberger Comprehensive Cancer Center — CureCurrent

How to interpret these research links

Connected source records

The exact organization name UNC Lineberger Comprehensive Cancer Center appears in 163 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials163

Recruiting shown33

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Pharmacologic Therapies to Mitigate Radiation- Associated Heart DiseaseNCT07685938 · lead sponsor · 2026-08-12

Effects of Infusion Timing on Treatment Response in Solid TumorsNCT07630168 · lead sponsor · 2026-08-03

Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation OncologyNCT07463833 · lead sponsor · 2026-06-22

Tirzepatide in Obesity-Driven Endometrial CancerNCT07065552 · lead sponsor · 2026-04-27

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast CancerNCT07276880 · lead sponsor · 2026-03-17

PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseNCT07069595 · lead sponsor · 2026-02-26

Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesNCT07340541 · lead sponsor · 2026-02-16

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIVNCT07428330 · lead sponsor · 2026-02-03

Nutrition Awareness Among Women With Non-Metastatic Breast CancerNCT07389967 · lead sponsor · 2026-01-20

Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase ExerciseNCT07313306 · lead sponsor · 2025-12-15

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) ImagingNCT07225114 · lead sponsor · 2025-11-04

Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer SurvivorsNCT06848491 · lead sponsor · 2025-10-27

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast CancerNCT07025785 · lead sponsor · 2025-08-22

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast CancerNCT06727773 · lead sponsor · 2025-08-19

Expanding the Support of Family Caregivers of Diverse Patients With Cancer and DiabetesNCT07061652 · lead sponsor · 2025-07-03

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and SurvivalNCT06896162 · lead sponsor · 2025-06-27

Designing Visual Tools to Enhance Cancer Surgeon Decision-makingNCT06965192 · lead sponsor · 2025-04-24

VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer PatientsNCT06878547 · lead sponsor · 2025-03-07

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)NCT06902311 · lead sponsor · 2025-02-19

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)NCT06855654 · lead sponsor · 2025-01-01

A Novel Approach Utilizing Organ Specific Age ProteomicsNCT06789653 · lead sponsor · 2024-10-10

BREAST Choice Decision Tool R21 - AIM2NCT06817226 · lead sponsor · 2024-10-10

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T CellsNCT06347068 · lead sponsor · 2024-06-27

Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer StudyNCT07214610 · lead sponsor · 2023-11-28

ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerNCT05542407 · lead sponsor · 2023-10-23

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung CancerNCT05620342 · lead sponsor · 2023-06-21

Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South AfricaNCT05413798 · lead sponsor · 2023-05-11

Study of Trilaciclib and LurbinectidinNCT05578326 · lead sponsor · 2022-10-12

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among CliniciansNCT05440929 · lead sponsor · 2022-07-07

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyNCT05472792 · lead sponsor · 2022-05-17

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCANCT03769415 · lead sponsor · 2018-11-06

UNC Pleural Fluid RegistryNCT05620329 · lead sponsor · 2018-01-24

Correlation of Molecular Markers With Response to Therapy and Breast Cancer BehaviorNCT01000883 · lead sponsor · 1998-12-01

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabNCT04266730 · lead sponsor · 2027-05-20

Optimization of Dietary Adherence in a Mobile Weight Loss InterventionNCT07582536 · lead sponsor · 2027-03-01

NOT_YET_RECRUITING

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNCT07078838 · lead sponsor · 2027-01-01

NOT_YET_RECRUITING

Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLCNCT07639242 · lead sponsor · 2026-10-01

C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United StatesNCT07520188 · lead sponsor · 2026-09-10

NOT_YET_RECRUITING

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women Living With HIVNCT07624123 · lead sponsor · 2026-09-01

NOT_YET_RECRUITING

Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in KenyaNCT07545746 · lead sponsor · 2026-09-01

NOT_YET_RECRUITING

HomeGrown: A Family-based Lifestyle Intervention to Support Healthy Development of Young Children With Down SyndromeNCT07296861 · lead sponsor · 2026-04-16

ACTIVE_NOT_RECRUITING

Dissemination of BREASTChoice AIM1-BNCT07396766 · lead sponsor · 2025-10-01

Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive InterventionsNCT05751993 · lead sponsor · 2025-04-12

Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in KenyaNCT06519994 · lead sponsor · 2025-01-22

VisR for Noninvasively Interrogating Stromal Collagen Organization as a Breast Cancer Biomarker: Evaluation of Compression in Control SubjectsNCT06547034 · lead sponsor · 2024-10-16

Abequolixron (RGX-104) and Durvalumab in Lung CancerNCT05911308 · lead sponsor · 2024-04-01

Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer SurvivorsNCT06171945 · lead sponsor · 2024-03-01

The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer TreatmentNCT06096623 · lead sponsor · 2023-11-06

5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East AfricaNCT05362955 · lead sponsor · 2023-04-26

Kaposi Sarcoma Chemotherapy and Research (KS-CARE)NCT06480773 · lead sponsor · 2023-04-25

ACTIVE_NOT_RECRUITING

Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIVNCT05413811 · lead sponsor · 2023-03-22

Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast CancerNCT05755347 · lead sponsor · 2023-03-17

Risk Stratification for Patients With Hospital-diagnosed Advanced Lung CancerNCT05722847 · lead sponsor · 2023-03-14

Comparison of CE-DBT and MRI in Patients With Known Breast LesionsNCT05754749 · lead sponsor · 2023-03-13

Evaluation of Child Care Staff Weight Management ProgramNCT05656807 · lead sponsor · 2023-01-18

ACTIVE_NOT_RECRUITING

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary TreatmentNCT05926024 · lead sponsor · 2023-01-06

ACTIVE_NOT_RECRUITING

Adaptation of a Values Assessment ToolNCT07068477 · lead sponsor · 2023-01-05

PSMA-PET/MRI Low- and Intermediate-Risk Prostate CancerNCT04243941 · lead sponsor · 2022-11-29

Physical Function During ARSI TreatmentNCT05612880 · lead sponsor · 2022-10-13

Metastatic Breast Cancer-Specific Prognostic ToolNCT05574478 · lead sponsor · 2022-09-20

Drugs studied in this sponsor's trials

49 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing UNC Lineberger Comprehensive Cancer Center as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

carboplatin9

cyclophosphamide5

paclitaxel5

pembrolizumab5

docetaxel3

erlotinib hydrochloride3

placebo3

trastuzumab3

carboplatin RxCUI 40048 · Lead sponsor in 9 linked trial(s) · 0 currently recruiting 9 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 5 linked trial(s) · 1 currently recruiting 5 trials paclitaxel RxCUI 56946 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials docetaxel RxCUI 72962 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials erlotinib hydrochloride RxCUI 477320 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials placebo RxCUI 8375 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials trastuzumab RxCUI 224905 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials Abraxane RxCUI 589511 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials capecitabine RxCUI 194000 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials gallium GA-68 gozetotide RxCUI 2586016 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials lapatinib RxCUI 480167 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials lapatinib ditosylate RxCUI 481474 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials memantine RxCUI 6719 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials pemetrexed disodium RxCUI 282443 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials tirzepatide RxCUI 2601723 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials aprepitant RxCUI 358255 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial atezolizumab RxCUI 1792776 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial celecoxib RxCUI 140587 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cetuximab RxCUI 318341 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial citalopram RxCUI 2556 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial datopotamab deruxtecan RxCUI 2703033 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial Doxil RxCUI 80773 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial doxorubicin RxCUI 3639 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor157

collaborator6

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.